|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS12335 |
| 應(yīng)用范圍 | ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-SUFU/Suppressor of Fused |
| 克隆性 | 是 |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human SUFU(433-485 aa) |
抗體的生物素化標(biāo)記實驗要點(diǎn)：
1. 抑制Hh信號通路蛋白SUFU抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時,或位于酶的催化位點(diǎn)時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
產(chǎn)品訂購信息：
英文名稱 Anti-SUFU/Suppressor of Fused
中文名稱 抑制Hh信號通路蛋白SUFU抗體品牌
別 名 SU FU; SU(F)U; Su(fu); SUFU; SUFU_HUMAN; SUFUH; SUFUXL; Suppressor of fused homolog (Drosophila); Suppressor of fused homolog; OTTHUMP00000020374; OTTHUMP00000020377; OTTHUMP00000020379; PRO1280.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Pig, Horse
產(chǎn)品類型 一抗
研究領(lǐng)域 轉(zhuǎn)錄調(diào)節(jié)因子 表觀遺傳學(xué)
蛋白分子量 predicted molecular weight: 53, 106kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human SUFU(433-485 aa)
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
抑制Hh信號通路蛋白SUFU抗體品牌 產(chǎn)品應(yīng)用 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 SUFU is a key negative regulator in the vertebrate Hedgehog signaling pathway. SUFU interacts with genes encoding proteins in this signal transduction pathway. In Drosophila, Intracellular transduction of the Hedgehog pathway involves the release of a large complex containing SUFU. SUFU inhibits the activity of the transcription factor Gli1 and interacts with Gli2, Gli3 and the serine/threonine kinase Fused. SUFU is widely expressed in adult and embryonic tissues with higher expression in tissues patterned by hegdehog signaling. The SUFU gene locus maps to a region that is deleted in glioblastomas, prostate cancer, malignant melanoma and endometrial cancer.
Function : Negative regulator in the hedgehog signaling pathway. Down-regulates GLI1-mediated transactivation of target genes. Part of a corepressor complex that acts on DNA-bound GLI1. May also act by linking GLI1 to BTRC and thereby targeting GLI1 to degradation by the proteasome. Sequesters GLI1, GLI2 and GLI3 in the cytoplasm, this effect is overcome by binding of STK36 to both SUFU and a GLI protein. Negative regulator of beta-catenin signaling. Regulates the formation of either the repressor form (GLI3R) or the activator form (GLI3A) of the full length form of GLI3 (GLI3FL). GLI3FL is complexed with SUFU in the cytoplasm and is maintained in a neutral state. Without the Hh signal, the SUFU-GLI3 complex is recruited to cilia, leading to the efficient processing of GLI3FL into GLI3R. When Hh signaling is initiated, SUFU dissociates from GLI3FL and the latter translocates to the nucleus, where it is phosphorylated, destabilized, and converted to a transcriptional activator (GLI3A).
Subunit : May form homodimers. Part of a DNA-bound corepressor complex containing SAP18, GLI1 and SIN3. Part of a complex containing CTNNB1. Binds BTRC, GLI2, GLI3, SAP18 and STK36. Binds both free and DNA-bound GLI1. Interacts with KIF7. Interacts with GLI3FL and this interaction regulates the formation of either repressor or activator forms of GLI3. Its association with GLI3FL is regulated by Hh signaling and dissociation of the SUFU-GLI3 interaction requires the presence of the ciliary motor KIF3A. Interacts with ULK3; inactivating the protein kinase activity of ULK3.
Subcellular Location : Cytoplasm. Nucleus.
Tissue Specificity : Ubiquitous in adult tissues. Detected in osteoblasts of the perichondrium in the developing limb of 12-week old embryos. Isoform 1 is detected in fetal brain, lung, kidney and testis. Isoform 2 is detected in fetal testis, and at much lower levels in fetal brain, lung and kidney.
DISEASE : Defects in SUFU are a cause of medulloblastoma (MDB) [MIM:155255]. MDB is a malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children. Defects in SUFU play a role in predisposition to desmoplastic MDB. These tumors make up about 20 to 30% of medulloblastomas, have a more nodular architecture than 'classical' medulloblastoma, and may have a better prognosis.
Similarity : Belongs to the SUFU family.
抗體的鑒定：
1）抑制Hh信號通路蛋白SUFU抗體品牌 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴(kuò)散試驗來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力。抗體的特異性高,它的識別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。
哥倫比亞瓊脂培養(yǎng)基2406g滅菌后冷至45℃左右時加入5%脫纖維羊血，用于空腸彎曲菌的培養(yǎng)。(CP、GB、EP、USP)
2561-prf TEpiCM-prf 扁桃體上皮細(xì)胞培養(yǎng)基 500ml incubation media 2561-prf TEpiCM-prf 扁桃體上皮細(xì)胞培養(yǎng)基 500ml
改良馬丁培養(yǎng)基 300ml/袋*10 用于藥品及生物制品霉菌無菌檢驗
Pfizer腸球菌選擇性瓊脂(PSE瓊脂)250g用于糞鏈球菌的選擇性分離和計數(shù)(SN標(biāo)準(zhǔn))
GCAgar
哥倫比亞瓊脂培養(yǎng)基2406g用于營養(yǎng)要求較高的細(xì)菌的培養(yǎng)及溶血試驗，還用于藥品中梭菌的檢測。(《中華人民共和國藥典》201...
TYGPN Medium 培養(yǎng)基 250g incubation media TYGPN Medium 培養(yǎng)基 250g
玉蕈、真姬菇 支/瓶
腸道菌增菌肉湯(EE)250g用于腸道菌的增菌培養(yǎng)(FDA、SN標(biāo)準(zhǔn))
GVPC瓊脂基礎(chǔ)添加劑 5支/套 每套添加于100mlGVPC瓊脂中
大豆酪蛋白消化物瓊脂培養(yǎng)基250g用于藥品中需氧菌總數(shù)測定
mEI瓊脂(腸球菌顯色培養(yǎng)基) 1000mL/瓶 incubation media mEI瓊脂(腸球菌顯色培養(yǎng)基) 1000mL/瓶
哥倫比亞瓊脂培養(yǎng)基 250g 用于營養(yǎng)要求較高的細(xì)菌的培養(yǎng)及溶血試驗，還用于藥品中梭菌的檢測。(《中華人民共和國藥典》201...
瓊脂培養(yǎng)基JAgarmediumJ(Deoxycholatecitrateagar)用于沙門氏菌選擇性分離培養(yǎng)
M17Agar
CL-0236U-2 OS(人細(xì)胞)5×106cells/瓶×2
IL1R1 Others Human 人 IL1R1 / CD121a 人細(xì)胞裂解液 (陽性對照)
人肺動脈成纖維細(xì)胞cDNAHPAF cDNA
HCC38細(xì)胞，人導(dǎo)管癌細(xì)胞 昆蟲細(xì)胞系,SF-9細(xì)胞 肝動脈內(nèi)皮細(xì)胞Many types of cells包裝：5 × 105次方(1ml)
293E(人胚腎細(xì)胞(EBNA1基因修飾)) 5×106cells/瓶×2
HBMEC Pellet 正常人腦部微內(nèi)皮細(xì)胞團(tuán)塊 > 1 mio.cells EpiFectagen? 上皮細(xì)胞轉(zhuǎn)染試劑盒
抑制Hh信號通路蛋白SUFU抗體品牌CL-0234TM3(小鼠間質(zhì)細(xì)胞)5×106cells/瓶×2
KIT Others Human 人 KIT / c-KIT / CD117 人細(xì)胞裂解液 (陽性對照)
人肺動脈內(nèi)皮細(xì)胞cDNAHPAEC cDNA
小鼠髖動脈內(nèi)皮細(xì)胞;PIEC 細(xì)胞，RBL-2H3細(xì)胞 ME細(xì)胞，C57小鼠瘤株
Sars結(jié)構(gòu)蛋白表達(dá)株;293 001B
HA Others H1N1 甲型 H1N1 (A/Puerto Rico/8/1934) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽性對照)
|
|
|
|
|
